All In Biotech

Drug Trial Radar · NCT04105010

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients With Peripheral T Cell Lymphoma (PTCL)

Last checked: Nov 19, 2026Latest source record: Apr 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

171

Actual

Start

Sep 10, 2019

Primary completion

Oct 12, 2023

Study completion Feb 22, 2024

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multinational, non-randomized, open-label, Phase 1/2 clinical study to evaluate the safety, tolerability and anti-tumor efficacy of AZD4205 as monotherapy in patients with peripheral T cell lymphoma (PTCL), who have relapsed from or are refractory/intolerant to standard systemic treatment. Phase 1 part: Around 20\~40 patients will be subsequently enrolled into 2 different dose ascending cohorts. Additional 10\~20 patients may be enrolled to further explore a selected dose defined by dose escalation cohorts. Phase 2 part: After the recommended phase 2 dose (RP2D) is defined, a phase 2 single-arm open-label pivotal study will be conducted to assess anti-tumor efficacy and safety of AZD4205 at RP2D in patients with refractory or relapsed PTCL.

Conditions

  • Relapsed or Refractory Peripheral T Cell Lymphoma

Interventions

  • golidocitinibDrug

    golidocitinib will be administered orally as capsules. golidocitinib treatment will be continued until disease progression or intolerant adverse reactions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part B: CT-based Objective Response Rate (ORR) by Independent Review Committee (IRC)Time frame: Up to approximately 3 years

Locations

50 sites in 4 countries. Site status is shown where the registry gives one.

  • Yale Cancer Center

    New Haven, Connecticut

  • Winship Cancer Institute

    Atlanta, Georgia

  • Washington University School of Medicine

    St Louis, Missouri

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Epworth Hospital

    East Melbourne, Australia

  • St Vincent's Hospital Melbourne

    Fitzroy, Australia

  • Royal Hobart Hospital

    Hobart, Australia

  • St George Hospital

    Kogarah, Australia

  • Royal Perth Hospital

    Perth, Australia

  • Westmead Hospital

    Westmead, Australia

  • Beijing Cancer Hospital

    Beijing, China

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, China

  • Beijing Hospital

    Beijing, China

  • Peking University Third Hospital

    Beijing, China

  • The First Hospital of Jilin University

    Changchun, China

  • Hunan Cancer Hospital

    Changsha, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Sichuan University - West China Hospital

    Chengdu, China

  • Chongqing University Cancer Hospital

    Chongqing, China

  • The Second Hospital of Dalian Medical University

    Dalian, China

  • Guangdong Provincial People's Hospital

    Guangzhou, China

  • NanFang Hospital of Southern Medical University

    Guangzhou, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, China

  • Hainan General Hospital

    Haikou, China

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, China

  • Zhejiang Cancer Hospital

    Hangzhou, China

  • Anhui Provincial Cancer Hospital

    Hefei, China

  • The Second Hospital of Anhui Medical University

    Hefei, China

  • Shandong Cancer Hospital

    Jinan, China

  • The First Hospital of Lanzhou University

    Lanzhou, China

  • Linyi Cancer Hospital

    Linyi, China

  • Jiangxi Province Cancer Hospital

    Nanchang, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, China

  • Jiangsu Cancer Hospital

    Nanjing, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • Ruijin Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, China

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, China

Showing 40 of 50 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.